In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals in Depth: August 2009

Executive Summary

The month of August saw pharmaceutical deal values go down. The highest-valued deal was Forest Laboratories' US license to Nycomed's COPD candidate Daxas, which included $100mm up front and $500mm in total milestones. Acquisition volume decreased, across both biopharma and device. Still P&G managed to get $3.1bn in cash by selling its branded drug business to Warner Chilcott. In financings, public offerings continued last month's growth with three transactions in August--from Seattle Genetics, Onyx, and Inspire--netting over $100mm each. In addition, D-Pharm and Cumberland completed the first two pharma IPOs in over a year.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts